Abstract
The association of myopathy with epsilon-aminocaproic acid (EACA) treatment after subarachnoid hemorrhage in two cases is reported. Clinical and laboratory findings and possible mechanisms are discussed in light of the known pharmacology of the drug. Recovery ensues if EACA treatment is terminated as soon as myopathy appears.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
